Similar articles

• AN 448 Sandoz (Mazindol) in the treatment of obesity.

  Wallace AG. Wallace AG. Med J Aust. 1976 Mar 13;1(11):343-5. Med J Aust. 1976. PMID: 775265 Clinical Trial.
• [Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].

  Riesco J, Troncoso G, Costamaillere L, Rodríguez J. Riesco J, et al. Rev Med Chil. 1977 Jun;105(6):375-9. Rev Med Chil. 1977. PMID: 331428 Clinical Trial. Spanish. No abstract available.
• [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].

  Gołebiowska M, Chlebna-Sokół D, Kobierska I, Konopińska A, Małek M, Mastalska A, Zwaigzne-Raczyńska J. Gołebiowska M, et al. Przegl Lek. 1981;38(3):355-8. Przegl Lek. 1981. PMID: 7017827 Clinical Trial. Polish. No abstract available.
• Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.

  Inoue S, Egawa M, Satoh S, Saito M, Suzuki H, Kumahara Y, Abe M, Kumagai A, Goto Y, Shizume K. Inoue S, et al. Am J Clin Nutr. 1992 Jan;55(1 Suppl):199S-202S. doi: 10.1093/ajcn/55.1.199s. Am J Clin Nutr. 1992. PMID: 1728834 Review.
• Obesity.

  Arterburn D. Arterburn D. Clin Evid. 2003 Dec;(10):676-89. Clin Evid. 2003. Update in: Clin Evid. 2004 Jun;(11):762-76. PMID: 15555115 Updated. Review. No abstract available.